The installation of the first HemoCell in Greece marked a significant milestone for both Werfen and Antisel.
In recognition of World Hemophilia Day on April 17, we launched an awareness campaign centered around two key initiatives:
The landscape of laboratory medicine is in continuous evolution. Demands of the laboratory continue to increase while resources and laboratory technicians are becoming scarce resources.
Werfen through its team in EEMEA and Italy, continued its commitment to advancing the fight against cancer-related blood clots by being a bronze sponsor at the recently concluded 12th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC 2024).
Werfen has received 510(k) clearance from the US Food and Drug Administration (FDA), and CE Mark (based on compliance with the In Vitro Diagnostic Regulation (IVDR)), for the HemosIL Chromogenic Factor IX assay,
The Werfen team has completed a major competitive conversion in North America, at CommonSpirit Health. As the second largest health system in the US, CommonSpirit comprises 142 hospitals across 21 states.
In 2024 Werfen EEMEA has launched its first Digital Campaign, as a detailed and phased approach, to enhance its digital presence and strengthen partnerships with customers on HemoHub – Intelligent Data Manager.
In a significant achievement, Werfen & AFMS has recently marked a great victory in a coagulation tender for Sulaiman Habib Group, the largest private hospital chain in the Kingdom of Saudi Arabia.
2023 marked a pivotal year for HemoHub, achieving 8x installations in a year, a testament to the company's robust and strategic marketing efforts. This remarkable success can be traced back to 2019 when HemoHub initiated a series of marketing activities that laid the foundation for this growth.

